Skip to main content

Advertisement

Table 4 Cox proportional hazards model of relative hazards of re-infection during 28 day follow-up (946 patients).

From: Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

Variable Relative hazard 95%CI p-value p-value (trend)
   lower upper   
unsupervised treatment 1.77 0.82 3.79 0.144  
age group      <0.001
   15 years and above 1.00 [reference]     
   5–14 years 4.05 1.10 14.94 0.036  
   <5 years 8.44 2.71 26.27 <0.001  
lumefantrine dose (mg/Kg)      0.003
   ≥80 1.00 [reference]     
   65–79 7.50 0.95 59.12 0.056  
   50–64 13.95 1.82 106.65 0.011  
   <50 12.72 1.08 150.22 0.043